<?xml version="1.0" encoding="UTF-8"?>
<p>Based on the aforementioned data, guidance from AGA and expert advice suggests that daily doses of GCs &gt;20 mg prednisolone equivalents for treatment durations &gt;4 weeks should be considered as having at least moderate risk for HBVr and warrant antiviral prophylaxis in HBsAg positive patients.
 <sup>
  <xref rid="bibr17-1759720X20912646" ref-type="bibr">17</xref>,
  <xref rid="bibr33-1759720X20912646" ref-type="bibr">33</xref>
 </sup> On the contrary, the risk is low in HBsAg negative/anti-HBc positive patients and monitoring, rather than prophylaxis treatment, is advised.
</p>
